Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04323189 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Effects of Sitagliptin in Individuals With Genetically Decreased DPP4

StatusActive, Not Recruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

  1. Secondary endpoints: 8 to 7 Study description shortened, about 36 wordsv11 Show 1 more changeShow less
    • Study description shortened, about 36 words

    See this version in full on ClinicalTrials.gov ↗

  2. Primary completion date: Dec 2, 2024 to Feb 27, 2025v10
  3. Trial status: Recruiting to Active, Not Recruiting Primary completion date changed from estimate of Sep 2, 2024 to Dec 2, 2024 · Completion date: Dec 31, 2024 to Feb 28, 2026 · Site details revisedv9 Show 3 more changesShow less
    • Primary completion date changed from estimate of Sep 2, 2024 to Dec 2, 2024
    • Completion date: Dec 31, 2024 to Feb 28, 2026
    • Site details revised
  4. Primary completion date: Mar 31, 2024 to Sep 2, 2024v8
  5. Primary completion date: Jan 30, 2024 to Mar 31, 2024 Completion date: Feb 1, 2024 to Dec 31, 2024v7 Show 1 more changeShow less
    • Completion date: Feb 1, 2024 to Dec 31, 2024
Show 5 earlier versionsHide 5 earlier versions
  1. Primary completion date: Jan 30, 2023 to Jan 30, 2024 Completion date: Jul 1, 2023 to Feb 1, 2024v6 Show 1 more changeShow less
    • Completion date: Jul 1, 2023 to Feb 1, 2024
  2. Re-verified, no change to tracked fieldsv5
  3. Start date: Mar 1, 2020 to Aug 26, 2020 Primary completion date: Dec 30, 2023 to Jan 30, 2023 · Completion date: Dec 30, 2023 to Jul 1, 2023v4 Show 2 more changesShow less
    • Primary completion date: Dec 30, 2023 to Jan 30, 2023
    • Completion date: Dec 30, 2023 to Jul 1, 2023
  4. Trial status: Suspended to Recruiting Site details revisedv3 Show 1 more changeShow less
    • Site details revised
  5. Sponsor's reason: coronavirus precautions, clinical research center closed to holding enrollment related to coronavirus changesv2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a pilot clinical trial to test the hypothesis that during sitagliptin (DPP4 inhibitor), individuals heterozygous for DPP4 loss of function variants will have a reduction in DPP4 activity and antigen, lower glucose after a mixed meal, and higher levels of intact DPP4 substrates compared to during placebo and compared to matched controls.
Trial Details
NCT Number NCT04323189
Lead Sponsor University of Pennsylvania
Conditions Genetics Disease, Type2 Diabetes, Heart Failure
Enrollment 20 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov